Under construction – not a live service
Sign in
Taking people in PakistanPhase 2

Tests thalidomide at different doses in people with transfusion-dependent beta thalassemia

Studies low-dose thalidomide in people aged 8 to 35 with transfusion-dependent beta thalassemia.

Plain-language title generated from the registry record
Registry title: Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

Key facts

Where
Karachi, PakistanSee the site
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 8 and 35 years old?

Source: NCT06490627, who can take part

Where in Pakistan

  • National Institute of blood disease and bone marrow transplantKarachi, PakistanTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Trial code
NCT06490627
Record updated
30 May 2025
Original description
The project "Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia" investigates the safety and efficacy of low-dose thalidomide in managing beta thalassemia, a genetic disorder causing anemia. Conducted over two years at NIBD hospital, the study involves 54 transfusion-dependent patients aged 8-35. The primary objective is to correlate thalidomide doses with disease severity, adverse effects, and treatment response, aiming to optimize treatment strategies and reduce side effects.Read full original descriptionShow less

Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

The project "Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia" investigates the safety and efficacy of low-dose thalidomide in managing beta thalassemia, a genetic disorder causing anemia. Conducted over two years at NIBD hospital, the study involves 54 transfusion-dependent patients aged 8-35. The primary objective is to correlate thalidomide doses with disease severity, adverse effects, and treatment response, aiming to optimize treatment strategies and reduce side effects.

Data will be collected through clinical interviews and medical record reviews and analyzed using SPSS. Key variables include hemoglobin levels, leukocyte and reticulocyte counts, platelets, liver and spleen size, genetic modifiers, and transfusion frequency. Inclusion criteria are specific to beta thalassemia patients, while exclusion criteria rule out those with liver dysfunction, married patients, lactating mothers, and those with a history of thrombosis or fits.

Inclusion: Know case of beta thalassemia major/ intermediate ( transfusion dependent); willing to give informed consent.

Exclusion: H/O thrombosis and fits; Patients with comorbidities such as liver dysfunction; Married patients; Lactating mother.

ClinicalTrials.gov NCT06490627